Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor, is Efficacious in Mouse Models of Lupus Nephritis and Reduces Human Lymphocyte Lifespan in vitro

被引：0
|
作者：
Wang, L. [1 ]
Perper, S. [1 ]
Grebe, K. [1 ]
Schwartz, A. [1 ]
Goess, C. [1 ]
O'Connor, L. [1 ]
Hartman, D. [1 ]
Westmoreland, S. [1 ]
Graff, C. [1 ]
Souers, A. [2 ]
Leverson, J. [2 ]
Elmore, S. [2 ]
Olson, L. [1 ]
机构：
[1] Abbvie Inc, Worcester, MA USA
[2] Abbvie Inc, N Chicago, IL USA
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P4.24
引用
收藏
页码：S34 / S34
页数：1
相关论文
共 50 条
  • [1] Venetoclax (ABT-199), a potent and selective BCL-2 inhibitor, is efficacious in NZB/WF1 mouse model of lupus nephritis and reduces human lymphocyte lifespan in vitro
    Grebe, Kristie
    Perper, Stuart
    O'Connor, Liz
    Schwartz, Annette
    Goess, Christian
    Hartman, Dawna
    Westmoreland, Susan
    Graff, Candace
    Souers, Andrew
    Leverson, Joel
    Elmore, Steven
    Olson, Lisa
    Wang, Lichun
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [2] VENETOCLAX (ABT-199), A POTENT AND SELECTIVE BCL-2 INHIBITOR, PREVENTS NEPHRITIS IN LUPUS PRONE NZB/W F1 MICE BY DEPLETING SELECTIVE LYMPHOCYTE POPULATIONS WHILE SPARING PLATELETS
    Wang, L. C.
    Perper, S.
    Schwartz, A.
    Goess, C.
    O'Connor, L.
    Hartman, D.
    Graff, C.
    Souers, A.
    Leverson, J.
    Elmore, S.
    Olson, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 334 - 334
  • [3] Lymphocyte Depletion, Recovery and Efficacy in NZBWF1 Lupus Mice Following Continuous or Intermittent Dosing Regimen of Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor
    Wang, Li Chun
    Perper, Stuart
    Black, Kimberly
    Mario, Regina
    Graff, Candace
    Hartman, Dawna
    Souers, Andrew
    Elmore, Steven
    Olson, Lisa
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [4] Lymphocyte depletion, recovery and efficacy in NZBWF1 lupus mice following continuous or intermittent dosing regimen of Venetoclax (ABT-199), a potent and selective BCL-2 Inhibitor
    Wang, L.
    Perper, S.
    Black, K.
    Mario, R.
    Graff, C.
    Hartman, D.
    Souers, A.
    Elmore, S.
    Olson, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S33 - S33
  • [5] ABT-199, a Potent and Selective BCL-2 Inhibitor, Prevents Lupus Nephritis in the Spontaneous NZB/W F1 Mouse Model By Depleting Selective Lymphocyte Populations While Sparing Platelets.
    Wang, Li Chun
    Perper, Stuart
    Schwartz, Annette
    Goess, Christian
    O'connor, Liz
    Hartman, Dawna
    Graff, Candace
    Souers, Andrew
    Leverson, Joel
    Elmore, Steven
    Olson, Lisa
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S379 - S380
  • [6] ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
    Andrew J Souers
    Joel D Leverson
    Erwin R Boghaert
    Scott L Ackler
    Nathaniel D Catron
    Jun Chen
    Brian D Dayton
    Hong Ding
    Sari H Enschede
    Wayne J Fairbrother
    David C S Huang
    Sarah G Hymowitz
    Sha Jin
    Seong Lin Khaw
    Peter J Kovar
    Lloyd T Lam
    Jackie Lee
    Heather L Maecker
    Kennan C Marsh
    Kylie D Mason
    Michael J Mitten
    Paul M Nimmer
    Anatol Oleksijew
    Chang H Park
    Cheol-Min Park
    Darren C Phillips
    Andrew W Roberts
    Deepak Sampath
    John F Seymour
    Morey L Smith
    Gerard M Sullivan
    Stephen K Tahir
    Chris Tse
    Michael D Wendt
    Yu Xiao
    John C Xue
    Haichao Zhang
    Rod A Humerickhouse
    Saul H Rosenberg
    Steven W Elmore
    Nature Medicine, 2013, 19 : 202 - 208
  • [7] ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
    Souers, Andrew J.
    Leverson, Joel D.
    Boghaert, Erwin R.
    Ackler, Scott L.
    Catron, Nathaniel D.
    Chen, Jun
    Dayton, Brian D.
    Ding, Hong
    Enschede, Sari H.
    Fairbrother, Wayne J.
    Huang, David C. S.
    Hymowitz, Sarah G.
    Jin, Sha
    Khaw, Seong Lin
    Kovar, Peter J.
    Lam, Lloyd T.
    Lee, Jackie
    Maecker, Heather L.
    Marsh, Kennan C.
    Mason, Kylie D.
    Mitten, Michael J.
    Nimmer, Paul M.
    Oleksijew, Anatol
    Park, Chang H.
    Park, Cheol-Min
    Phillips, Darren C.
    Roberts, Andrew W.
    Sampath, Deepak
    Seymour, John F.
    Smith, Morey L.
    Sullivan, Gerard M.
    Tahir, Stephen K.
    Tse, Chris
    Wendt, Michael D.
    Xiao, Yu
    Xue, John C.
    Zhang, Haichao
    Humerickhouse, Rod A.
    Rosenberg, Saul H.
    Elmore, Steven W.
    NATURE MEDICINE, 2013, 19 (02) : 202 - 208
  • [8] A potent and selective small molecule inhibitor of MCL-1 sensitizes DLBCL cell lines to the BCL-2 selective inhibitor ABT-199
    Phillips, D. C.
    Xiao, Y.
    Lam, L.
    Litinovic, E.
    Roberts-Rapp, L.
    Souers, A. J.
    Leverson, J. D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 130 - 130
  • [9] Remarkable early clinical activity with the Bcl-2 selective inhibitor ABT-199: Proving the concept.
    Humerickhouse, Rod
    CANCER RESEARCH, 2013, 73 (08)
  • [10] ABT-199, a Selective Small Molecule Inhibitor of Bcl-2, Exhibits Efficacy in Bcl-2 Dependent Malignancies While Sparing Platelets
    Leverson, J.
    Souers, A.
    Boghaert, E.
    Phillips, D.
    Park, C.
    Wendt, M.
    Fairbrother, W.
    Humerickhouse, R.
    Roberts, A.
    Elmore, S.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 23 - 23
12345